These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 38857600)

  • 1. Conditional score approaches to errors-in-variables competing risks data in discrete time.
    Wen CC; Chen YH
    Stat Med; 2024 Aug; 43(18):3503-3523. PubMed ID: 38857600
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discrete-time survival data with longitudinal covariates.
    Wen CC; Chen YH
    Stat Med; 2020 Dec; 39(29):4372-4385. PubMed ID: 32871614
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simulation shows undesirable results for competing risks analysis with time-dependent covariates for clinical outcomes.
    Poguntke I; Schumacher M; Beyersmann J; Wolkewitz M
    BMC Med Res Methodol; 2018 Jul; 18(1):79. PubMed ID: 30012114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Semiparametric competing risks regression under interval censoring using the R package intccr.
    Park J; Bakoyannis G; Yiannoutsos CT
    Comput Methods Programs Biomed; 2019 May; 173():167-176. PubMed ID: 31046992
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Additive subdistribution hazards regression for competing risks data in case-cohort studies.
    Wogu AF; Li H; Zhao S; Nichols HB; Cai J
    Biometrics; 2023 Dec; 79(4):3010-3022. PubMed ID: 36606409
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subdistribution hazard models for competing risks in discrete time.
    Berger M; Schmid M; Welchowski T; Schmitz-Valckenberg S; Beyersmann J
    Biostatistics; 2020 Jul; 21(3):449-466. PubMed ID: 30418529
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Statistical Methods for Cohort Studies of CKD: Survival Analysis in the Setting of Competing Risks.
    Hsu JY; Roy JA; Xie D; Yang W; Shou H; Anderson AH; Landis JR; Jepson C; Wolf M; Isakova T; Rahman M; Feldman HI;
    Clin J Am Soc Nephrol; 2017 Jul; 12(7):1181-1189. PubMed ID: 28242844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Semiparametric accelerated failure time cure rate mixture models with competing risks.
    Choi S; Zhu L; Huang X
    Stat Med; 2018 Jan; 37(1):48-59. PubMed ID: 28983935
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Time-dependent covariates in the proportional subdistribution hazards model for competing risks.
    Beyersmann J; Schumacher M
    Biostatistics; 2008 Oct; 9(4):765-76. PubMed ID: 18434297
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tree-based models for survival data with competing risks.
    Kretowska M
    Comput Methods Programs Biomed; 2018 Jun; 159():185-198. PubMed ID: 29650312
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The importance of censoring in competing risks analysis of the subdistribution hazard.
    Donoghoe MW; Gebski V
    BMC Med Res Methodol; 2017 Apr; 17(1):52. PubMed ID: 28376736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A dependent Dirichlet process model for survival data with competing risks.
    Shi Y; Laud P; Neuner J
    Lifetime Data Anal; 2021 Jan; 27(1):156-176. PubMed ID: 33044613
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A proportional hazards regression model for the subdistribution with right-censored and left-truncated competing risks data.
    Zhang X; Zhang MJ; Fine J
    Stat Med; 2011 Jul; 30(16):1933-51. PubMed ID: 21557288
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Additive-multiplicative hazards regression models for interval-censored semi-competing risks data with missing intermediate events.
    Kim J; Kim J; Kim SW
    BMC Med Res Methodol; 2019 Mar; 19(1):49. PubMed ID: 30841923
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis and design of randomised clinical trials involving competing risks endpoints.
    Tai BC; Wee J; Machin D
    Trials; 2011 May; 12():127. PubMed ID: 21595883
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estimating sample size in the presence of competing risks - Cause-specific hazard or cumulative incidence approach?
    Tai BC; Chen ZJ; Machin D
    Stat Methods Med Res; 2018 Jan; 27(1):114-125. PubMed ID: 26711503
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Practical recommendations for reporting Fine-Gray model analyses for competing risk data.
    Austin PC; Fine JP
    Stat Med; 2017 Nov; 36(27):4391-4400. PubMed ID: 28913837
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Boosting for high-dimensional time-to-event data with competing risks.
    Binder H; Allignol A; Schumacher M; Beyersmann J
    Bioinformatics; 2009 Apr; 25(7):890-6. PubMed ID: 19244389
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Competing time-to-event endpoints in cardiology trials: a simulation study to illustrate the importance of an adequate statistical analysis.
    Rauch G; Kieser M; Ulrich S; Doherty P; Rauch B; Schneider S; Riemer T; Senges J
    Eur J Prev Cardiol; 2014 Jan; 21(1):74-80. PubMed ID: 22964966
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cause-specific cumulative incidence estimation and the fine and gray model under both left truncation and right censoring.
    Geskus RB
    Biometrics; 2011 Mar; 67(1):39-49. PubMed ID: 20377575
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.